Amid the rising scare induced by the Omicron variant, Moderna, Inc., (MRNA) revealed that it is working rapidly to test whether the currently authorized dosage level of its booster shot is sufficient to neutralize the variant. The Omicron variant includes mutations seen in the Delta variant, which are likely to increase transmissibility, and mutations seen in the Beta and Delta variants, which promote immune escape. Moderna’s CEO, Stephane Bancel, said, “From the beginning, we have said that as we seek to defeat the pandemic, it is imperative that we are proactive as the virus evolves.
https://www.tipranks.com/news/moderna-reveals-strategy-to-neutralize-omicron-variant?utm_source=advfn.com&utm_medium=referral
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Moderna Charts.